Home/Pipeline/Endari (L-glutamine oral powder)

Endari (L-glutamine oral powder)

Sickle Cell Disease

ApprovedCommercial/Marketed

Key Facts

Indication

Sickle Cell Disease

Phase

Approved

Status

Commercial/Marketed

Company

Emmaus Life Sciences

About Emmaus Life Sciences

Emmaus Life Sciences is a biopharmaceutical company with a mission to develop and commercialize innovative therapies, initially for rare diseases. Its primary achievement is the 2017 FDA approval of Endari (L-glutamine oral powder) for sickle cell disease, establishing a commercial foundation. The company's strategy involves expanding Endari's global footprint, exploring its glutamine-based science in new indications like diverticulosis, and developing a novel cell sheet engineering platform. Recent leadership changes and a focus on financial improvement signal a period of strategic transition.

View full company profile

Therapeutic Areas

Hematology Gastroenterology

Other Sickle Cell Disease Drugs

Drug	Company	Phase	Status
ANXV	Annexin Pharmaceuticals	Research	Identified
Oxbryta® (voxelotor)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
CT-101	Cetya Therapeutics	Pre-clinical	Active - Lead candidate nominated
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Ramatroban (KAR101)	KARE Biosciences	Preclinical	Active
Digital Model for Sickle Cell Disease	Koneksa Health	Development/Validation	Active
ILX-002	Illexcor Therapeutics	Pre-clinical	Active
Epeleuton	Afimmune	Phase 2	Active
Undisclosed	Hillhurst Biopharmaceuticals	Preclinical or Phase 1	Active
CLY-124	Cellarity	Phase 1	Active
AB1	AkiraBio	Pre-clinical	Active
Oral Decitabine/Tetrahydrouridine	Novo Nordisk	Phase 2	Active